Living Cell Technologies Ltd. (LVCLF)
OTHER OTC:LVCLF
LVCLF Stock Chart & Stats
$0.01
>-$0.01(-68.75%)
At close: 4:00 PM EST
$0.01
>-$0.01(-68.75%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume10.00K
Average Volume (3M)N/A
Market Cap
$20.11M
Enterprise Value$27.99M
Total Cash (Recent Filing)$1.88M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.75
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding1,716,791,100
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-10.74
Enterprise Value/Market Cap1.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-13.70
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageHaving no debt materially lowers fixed financial obligations and interest expense, preserving flexibility to allocate scarce cash to R&D and clinical programs. Over 2–6 months this reduces insolvency risk and gives management optionality when sequencing trials or timing financings.
Improving Loss TrajectoryA material narrowing of net losses signals operational progress—either lower cash burn or more efficient program execution. If sustained, this trend reduces future financing needs and extends runway, improving odds management can reach clinical inflection points without excessive dilution.
Specialized Regenerative-Medicine PlatformA focused platform in encapsulated cell therapies addresses chronic diseases with high unmet need and regulatory pathways that reward clinical success. The niche technology creates technical barriers to entry and potential long-term licensing or partner opportunities if clinical milestones are achieved.
Bears Say
Absent Commercial RevenueLack of recurring commercial revenue means the business is not self-sustaining and must rely on external funding for operations. Over the medium term this increases execution risk, pressure to raise capital, and the likelihood of dilution before products generate sustainable sales.
Persistent Negative Cash FlowConsistent negative operating and free cash flow erodes cash reserves and shortens runway, forcing frequent financing or partnership choices. Structurally, ongoing cash burn constrains the pace of clinical development and heightens dependency on capital markets or dilutive funding over months.
Eroding Equity And Shrinking AssetsDeclining equity and shrinking asset bases reflect cumulative losses and weaken the balance sheet cushion. This reduces strategic flexibility to fund trials, negotiate partnerships, or absorb setbacks, raising the company's vulnerability to adverse clinical or funding events in the medium term.
Living Cell Technologies News
LVCLF FAQ
What was Living Cell Technologies Ltd.’s price range in the past 12 months?
Currently, no data Available
What is Living Cell Technologies Ltd.’s market cap?
Living Cell Technologies Ltd.’s market cap is $20.11M.
When is Living Cell Technologies Ltd.’s upcoming earnings report date?
Living Cell Technologies Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 158 days.
How were Living Cell Technologies Ltd.’s earnings last quarter?
Living Cell Technologies Ltd. released its earnings results on Mar 04, 2026. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Living Cell Technologies Ltd. overvalued?
According to Wall Street analysts Living Cell Technologies Ltd.’s price is currently Overvalued.
Does Living Cell Technologies Ltd. pay dividends?
Living Cell Technologies Ltd. does not currently pay dividends.
What is Living Cell Technologies Ltd.’s EPS estimate?
Living Cell Technologies Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Living Cell Technologies Ltd. have?
Living Cell Technologies Ltd. has 1,716,791,100 shares outstanding.
What happened to Living Cell Technologies Ltd.’s price movement after its last earnings report?
Living Cell Technologies Ltd. reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Living Cell Technologies Ltd.?
Currently, no hedge funds are holding shares in LVCLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Living Cell Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
LVCLF Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-49.25%
Trailing 12-Months
Asset Growth
-15.04%
Trailing 12-Months
Company Description
Living Cell Technologies Ltd.
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate coated capsule product for the treatment of Parkinson's disease. It is also developing AlgaraeOS in partnership with the University of New South Wales, a drug discovery platform that uses artificial intelligence protocols and big data analytics for drug discovery and development. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.
Invex Therapeutics Ltd.
―
Regeneus Ltd.
―
Chimeric Therapeutics Ltd.
―
Neuroscientific Biopharmaceuticals Ltd.
―
Memphasys Ltd
―